Esophageal squamous cell carcinoma
Conditions
Interventions
Reduced-dose Chemotherapy Combined with Immunotherapy Group:None
Sponsors
The First Affiliated Hospital of Sun Yat-Sen University
Eligibility
Sex/Gender
All
Age
70 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. The patient should have histologically proven esophageal squamous cell carcinoma and the lesion should be located in the thoracic esophagus; 2. Patients with clinical stage cT1b-cT2 with lymph node metastasis and without distant metastasis, cT3-cT4a with or without lymph node metastasis and without distant metastasis; 3. The patient should be >=70 years old with ECOG PS score of 0-1; 4. Normal function of major organ, including (a) hematology: neutrophil count >= 1.5 × 10^9/L, leukocyte count >= 3 × 10^9/L, platelet count >= 100 ×10^9/L; (b) blood biochemistry: total bilirubin =30 ml/min; 5. PET-CT or CT of neck, chest and upper abdomen; bone scan, brain CT/MR Imaging data of patients before and after neoadjuvant therapy should be complete; with clear staging and exclude distant metastasis; 6. Complete imaging and pathological data should be available.
Exclusion criteria
Exclusion criteria: 1. Receiving treatment options other than immunotherapy and chemotherapy, such as targeted therapy and radiation therapy; 2. Lack of imaging and pathological data; 3. Combine other diseases that affect treatment decisions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the incidence rate of treatment-related adverse events; | — |
Secondary
| Measure | Time frame |
|---|---|
| objective response rate;pathological complete response rate;progression-free survival;overall survival;disease control rate; | — |
Countries
China
Contacts
Public ContactChao Cheng
The First Affiliated Hospital of Sun Yat-Sen University
Outcome results
None listed